Company Profile
Rigel Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- RIGL
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
37.39 USD (+1.77%)
Close
Last updated: July 27, 2026
555M USD
Market cap
Why the stock is moving
The latest monitored company update is “Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results.” The corresponding closing-price reaction is not yet available.
Company overview
Business overview
Rigel Pharmaceuticals is a specialty pharmaceutical company with a commercial focus in hematology, inflammation, and related rare-disease settings. Its business combines marketed products with selective pipeline work.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Rigel sits in specialty biopharma.
Business Model Characteristics
The company depends on product revenue, label execution, and the ability to extend its commercial base with new assets.
Position Within the Biotechnology Landscape
Rigel is a commercial specialty-pharma name that trades on product durability and pipeline progress.
Future catalysts
Rigel’s catalysts are Rezlidhia and fostamatinib execution, plus any label or commercial update that can extend the hematology or immune-disease base. The stock usually responds when commercial traction looks durable.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results
Source: Rigel Pharmaceuticals
- 02
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GERN · Source: Geron
- 03
Geron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026
GERN · Source: Geron
- 04
Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®
ABEO · Source: Abeona Therapeutics
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Rigel Pharmaceuticals (RIGL)?
Rigel Pharmaceuticals (RIGL) most recently closed at 37.39 USD, a +1.77% move versus the previous session.
What is the market cap of Rigel Pharmaceuticals (RIGL)?
Rigel Pharmaceuticals currently has a market capitalization of 555M USD on BioPharmSignal.
What does Rigel Pharmaceuticals do?
Rigel Pharmaceuticals is a specialty pharmaceutical company with a commercial focus in hematology, inflammation, and related rare-disease settings. Its business combines marketed products with selective pipeline work.
On which exchange is RIGL stock listed?
Rigel Pharmaceuticals (RIGL) is associated with NASDAQ, United States, Biopharma.
What is fostamatinib?
Rigel’s catalysts are Rezlidhia and fostamatinib execution, plus any label or commercial update that can extend the hematology or immune-disease base.
Which conditions is Rigel Pharmaceuticals targeting with fostamatinib?
Rigel Pharmaceuticals is associated with inflammatory disease, hematology based on its company overview and current catalyst commentary.
How does Rigel Pharmaceuticals describe recent progress with fostamatinib?
Rigel’s catalysts are Rezlidhia and fostamatinib execution, plus any label or commercial update that can extend the hematology or immune-disease base.
What is Rigel?
Rigel Pharmaceuticals is a specialty pharmaceutical company with a commercial focus in hematology, inflammation, and related rare-disease settings.